These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8016818)

  • 1. Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin--results of a pilot study.
    Kirchmaier CM; Lindhoff-Last E; Rübesam D; Scharrer I; Vigh Z; Mosch G; Wolf H; Breddin HK
    Thromb Res; 1994 Mar; 73(5):337-48. PubMed ID: 8016818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis.
    Kakkar VV; Stringer MD; Hedges AR; Parker CJ; Welzel D; Ward VP; Sanderson RM; Cooper D; Kakkar S
    Am J Surg; 1989 Apr; 157(4):413-8. PubMed ID: 2539025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery.
    Lassen MR; Borris LC; Christiansen HM; Møller-Larsen F; Knudsen VE; Boris P; Nehen AM; de Carvalho A; Jurik AG; Nielsen BW
    Br J Surg; 1988 Jul; 75(7):686-9. PubMed ID: 2843255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen.
    Voth D; Schwarz M; Hahn K; Dei-Anang K; al Butmeh S; Wolf H
    Neurosurg Rev; 1992; 15(4):289-94. PubMed ID: 1336131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of deep vein thrombosis by low-molecular-weight heparin and dihydroergotamine in patients undergoing total hip replacement.
    Freick H; Haas S
    Thromb Res; 1991 Jul; 63(1):133-43. PubMed ID: 1658962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study.
    Thromb Haemost; 1991 Mar; 65(3):251-6. PubMed ID: 1646490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
    Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
    Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine.
    Haas S; Stemberger A; Fritsche HM; Welzel D; Wolf H; Lechner F; Blümel G
    Arzneimittelforschung; 1987 Jul; 37(7):839-43. PubMed ID: 2823840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroergotamine/heparin in the prevention of deep-vein thrombosis after total hip replacement. A controlled, prospective, randomized multicenter trial.
    Beisaw NE; Comerota AJ; Groth HE; Merli GJ; Weitz HH; Zimmerman RC; Diserio FJ; Sasahara AA
    J Bone Joint Surg Am; 1988 Jan; 70(1):2-10. PubMed ID: 3275673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg.
    Holmoström M; Berglund MC; Granquist S; Bratt G; Törnebohm E; Lockner D
    Thromb Res; 1992 Jul; 67(1):49-55. PubMed ID: 1332213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis.
    Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV
    Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.